The Federal Trade Commission has approved LabCorp’s $85.4 million acquisition of DNA testing firm Orchid Cellmark, but LabCorp had to agree to sell some assets in order to secure government approval.

LabCorp (NYSE: LH) agreed to buy Orchid Cellmark (Nasdaq: ORCH) in May, but the deal underwent an extensive FTC review.

As part of the agreement with the FTC, LabCorp said it will sell paternity testing business with the U.S. government to DNA Diagnostics Center. The firm provides DNA paternity testing, according to LabCorp.

The sale is to take place after the Orchid Cellmark acquisition closes.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.